UBS Reiterates Neutral Rating on Praxis Precision Medicines Inc. (PRAX)

October 14, 2026 4:45 PM EDT Send to a Friend
UBS reiterated a Neutral rating and $706.00 price target on Praxis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login